Zobrazeno 1 - 10
of 255
pro vyhledávání: '"Serena, Di Cosimo"'
Autor:
Serena Di Cosimo, Marco Silvestri, Cinzia De Marco, Alessia Calzoni, Maria Carmen De Santis, Maria Grazia Carnevale, Carolina Reduzzi, Massimo Cristofanilli, Vera Cappelletti
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Chromosomal Instability (CIN) is a common and evolving feature in breast cancer. Large-scale Transitions (LSTs), defined as chromosomal breakages leading to gains or losses of at least 10 Mb, have recently emerged as a metric of CIN due to t
Externí odkaz:
https://doaj.org/article/5e21cc35fec64b789fb53b1caf488296
Autor:
Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, Florence Dalenc, Miguel J. Gil Gil, Manuel Ruiz-Borrego, Joaquín Gavilá, Elena Aguirre, Peter Schmid, Frederik Marmé, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez de Dueñas, Kepa Amillano, Eileen Shimizu, Miguel Sampayo-Cordero, Javier Cortés, Antonio Llombart-Cussac
Publikováno v:
Breast, Vol 76, Iss , Pp 103761- (2024)
Background: The capsule formulation of CDK4/6 inhibitor palbociclib has reduced solubility at gastric pH > 4.5 and may have decreased activity when used with proton-pump inhibitors (PPI). Herein, we report the effect of PPI on palbociclib capsule act
Externí odkaz:
https://doaj.org/article/d3b96315025744e9a531e42906d8d57a
Autor:
Serena Di Cosimo, Sara Pizzamiglio, Chiara Maura Ciniselli, Valeria Duroni, Vera Cappelletti, Loris De Cecco, Cinzia De Marco, Marco Silvestri, Maria Carmen De Santis, Andrea Vingiani, Biagio Paolini, Rosaria Orlandi, Marilena Valeria Iorio, Giancarlo Pruneri, Paolo Verderio
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract In clinical trials evaluating antibody-conjugated drugs (ADCs), HER2-low breast cancer is defined through protein immunohistochemistry scoring (IHC) 1+ or 2+ without gene amplification. However, in daily practice, the accuracy of IHC is comp
Externí odkaz:
https://doaj.org/article/d7df224a01ee4e5988733bfc39acbfb0
Autor:
Mattia Rediti, Aranzazu Fernandez-Martinez, David Venet, Françoise Rothé, Katherine A. Hoadley, Joel S. Parker, Baljit Singh, Jordan D. Campbell, Karla V. Ballman, David W. Hillman, Eric P. Winer, Sarra El-Abed, Martine Piccart, Serena Di Cosimo, William Fraser Symmans, Ian E. Krop, Roberto Salgado, Sherene Loi, Lajos Pusztai, Charles M. Perou, Lisa A. Carey, Christos Sotiriou
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-18 (2023)
Abstract The identification of prognostic markers in patients receiving neoadjuvant therapy is crucial for treatment optimization in HER2-positive breast cancer, with the immune microenvironment being a key factor. Here, we investigate the complexity
Externí odkaz:
https://doaj.org/article/14a09996519f49368d11a06978543f0a
Autor:
Alberto Zambelli, Marina Cazzaniga, Nicla La Verde, Elisabetta Munzone, Ippazio Cosimo Antonazzo, Lorenzo Giovanni Mantovani, Serena Di Cosimo, Anna Mancuso, Daniele Generali, Paolo Angelo Cortesi
Publikováno v:
Breast, Vol 71, Iss , Pp 113-121 (2023)
Introduction: Clinical trials confirmed the beneficial effects of adding pertuzumab (P) to the combination of trastuzumab-chemotherapy (TC) in the (neo)adjuvant setting of high-risk HER2-positive early breast cancer (HER2+BC). We evaluated the clinic
Externí odkaz:
https://doaj.org/article/0aa2d78e2920415082d58a11e2d80f2f
Autor:
Serena Di Cosimo, Silva Ljevar, Annalisa Trama, Alice Bernasconi, Paolo Lasalvia, Maria Carmen De Santis, Vera Cappelletti, Rosalba Miceli, Giovanni Apolone
Publikováno v:
Breast, Vol 71, Iss , Pp 60-62 (2023)
We studied the COVID-19 impact in newly-diagnosed breast cancer (7,349 patients in 2019, and 5,563 in 2020). In 2020 there were two diagnostic drops: −37.2% (March–May), −15.8% (October–December). Early-stage at presentation (76.4% vs. 74.4%,
Externí odkaz:
https://doaj.org/article/2dfd854bcaf5433ea65f92e7d9c93f98
Autor:
Marco Silvestri, Trung Nghia Vu, Federico Nichetti, Monica Niger, Serena Di Cosimo, Filippo De Braud, Giancarlo Pruneri, Yudi Pawitan, Stefano Calza, Vera Cappelletti
Publikováno v:
Cancer Medicine, Vol 12, Iss 8, Pp 10156-10168 (2023)
Abstract Background Cholangiocarcinoma (CC) is a rare and aggressive disease with limited therapeutic options and a poor prognosis. All available public records of cohorts reporting transcriptomic data on intrahepatic cholangiocarcinoma (ICC) and ext
Externí odkaz:
https://doaj.org/article/e6283a90f55d4b91b0337654fc69c14a
Autor:
Tiziana Triulzi, Giampaolo Bianchini, Serena Di Cosimo, Tadeusz Pienkowski, Young‐Hyuck Im, Giulia Valeria Bianchi, Barbara Galbardi, Matteo Dugo, Loris De Cecco, Ling‐Ming Tseng, Mei‐Ching Liu, Begoña Bermejo, Vladimir Semiglazov, Giulia Viale, Juan de laHaba‐Rodriguez, Do‐Youn Oh, Brigitte Poirier, Pinuccia Valagussa, Luca Gianni, Elda Tagliabue
Publikováno v:
Molecular Oncology, Vol 16, Iss 12, Pp 2355-2366 (2022)
As most erb‐b2 receptor tyrosine kinase 2 (HER2)‐positive breast cancer (BC) patients currently receive dual HER2‐targeting added to neoadjuvant chemotherapy, improved methods for identifying individual response, and assisting postsurgical salv
Externí odkaz:
https://doaj.org/article/04d4128992ee4c3590607960b247f2b8
Autor:
Saranya Chumsri, Zhuo Li, Daniel J. Serie, Nadine Norton, Afshin Mashadi-Hossein, Kathleen Tenner, Heather Ann Brauer, Sarah Warren, Patrick Danaher, Gerardo Colon-Otero, Ann H. Partridge, Lisa A. Carey, Florentine Hilbers, Veerle Van Dooren, Eileen Holmes, Serena Di Cosimo, Olena Werner, Jens Bodo Huober, Amylou C. Dueck, Christos Sotiriou, Cristina Saura, Alvaro Moreno-Aspitia, Keith L. Knutson, Edith A. Perez, E. Aubrey Thompson
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-8 (2022)
Abstract Trastuzumab acts in part through the adaptive immune system. Previous studies showed that enrichment of immune-related gene expression was associated with improved outcomes in HER2-positive (HER2+) breast cancer. However, the role of the imm
Externí odkaz:
https://doaj.org/article/c541e25cb1954a448e8d1d99ad81395d
Autor:
Sara Pizzamiglio, Giulia Cosentino, Chiara M. Ciniselli, Loris De Cecco, Alessandra Cataldo, Ilaria Plantamura, Tiziana Triulzi, Sarra El‐abed, Yingbo Wang, Mohammed Bajji, Paolo Nuciforo, Jens Huober, Susan L. Ellard, David L. Rimm, Andrea Gombos, Maria Grazia Daidone, Paolo Verderio, Elda Tagliabue, Serena Di Cosimo, Marilena V. Iorio
Publikováno v:
Cancer Medicine, Vol 11, Iss 2, Pp 332-339 (2022)
Abstract Background Neoadjuvant therapy with dual HER2 blockade improved pathological complete response (pCR) rate in HER2‐positive breast cancer patients. Nevertheless, it would be desirable to identify patients exquisitely responsive to single ag
Externí odkaz:
https://doaj.org/article/bcbea9275b054d7d92ebc8e572fd0bc6